Bio-Rad Laboratories has announced the launch of its new cardiac control product Cardiac Advance. Designed to monitor the precision of instrument testing for cardiac events, this next generation control is optimized with Troponin I and T targets near the limit of instrument detection adhering to the latest guidelines set by AACC and IFCC. In addition, the Cardiac Advance control is consolidated with 10 of the most tested cardiac analytes including Troponin, CK-MB, BNP/ProBNP, and Myoglobin.
The Cardiac Advance control is available in multiple formats, including the standard Liquicheck human serum-based control as well as automation ready InteliQ and compact vial configurations designed to help streamline QC workflows to save time and resources.
Cardiac Advance controls are compatible with Siemens and Roche platforms and are available in the US, Europe, and select Asian markets. For more information on Cardiac Advance controls, contact a Bio-Rad sales representative or visit https://www.qcnet.com/cardiac.